Ketamine Shows Promise in Managing Parkinson’s Symptoms
Last reviewed and updated: August 17, 2026.
Key Takeaways
| The problem | Levodopa, the standard Parkinson’s treatment, can cause levodopa-induced dyskinesia, involuntary movements, after years of use. |
| The discovery | University of Arizona research first showed in a rat model that ketamine reduces these levodopa-induced involuntary movements. |
| Now in humans | A Phase 2 trial found a single low-dose ketamine infusion eased dyskinesia for several weeks and was well tolerated. |
| Moving forward | The work has an FDA Investigational New Drug clearance, the method has been licensed to a pharmaceutical company, and further trials are ongoing. |
| Still investigational | This is promising early research, not an approved or established treatment for Parkinson’s symptoms. |
Can ketamine, a drug known for its anesthetic and antidepressant properties, help address movement challenges in Parkinson’s disease? Recent research from the University of Arizona suggests it might. Scientists have found that ketamine reduces involuntary movements caused by L-DOPA, the standard treatment for Parkinson’s, in a rat model of the disease.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
L-DOPA, while effective at replenishing dopamine levels in the brain, can lead to uncontrollable movements called dyskinesias. These movements often develop after prolonged use, limiting the drug’s long-term effectiveness. The findings provide a potential path to improving the quality of life for Parkinson’s patients.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
How Does Ketamine Work in This Context?
Parkinson’s is characterized by the death of dopamine-producing neurons in the brain. While L-DOPA helps replace this lost dopamine, it can overstimulate certain neural pathways over time. Ketamine appears to act on a different system: the glutamate neurotransmitter system. By modulating this system, ketamine may help restore balance in brain signaling.
The researchers observed that even a single dose of ketamine reduced dyskinesias in the rat model. How might this discovery translate into human treatments? Could ketamine offer a safer alternative or complementary therapy for patients reliant on L-DOPA?
Balancing Benefits and Risks
Though promising, ketamine’s use in this context raises important questions. Known for its potential to cause side effects like hallucinations, ketamine must be carefully evaluated before becoming a mainstream option. How can researchers ensure its safety for long-term use in Parkinson’s patients? Clinical trials will be critical to answer these questions.
Read more of this this story at Genetic Engineering News.
The Path Ahead
The study marks an important step in exploring ketamine’s potential benefits beyond its current uses. It adds to a growing body of evidence that this drug, often associated with psychiatric applications, could play a role in treating neurodegenerative diseases.
What implications do findings like this have for patients and caregivers? Could they one day lead to less disruptive treatment options for Parkinson’s? While these questions remain unanswered, the research provides hope for a future where managing dyskinesias becomes less of a challenge.
As more studies build on this foundation, the potential for breakthroughs in Parkinson’s treatment continues to grow. Will ketamine become part of the solution? Only time and further research will tell.
Ketamine for Parkinson’s Dyskinesia: Where It Stands in 2026
Levodopa, the standard treatment for Parkinson’s, can cause levodopa-induced dyskinesia, involuntary movements that often develop after years of use. University of Arizona researchers first found in a rat model that ketamine reduces these levodopa-induced movements. That result pointed to a possible new use for the drug.
This research has advanced beyond animals. A Phase 2 trial at the University of Arizona, led by Scott Sherman and Torsten Falk, found that a single low-dose ketamine infusion eased levodopa-induced dyskinesia for several weeks. The infusion was well tolerated, with mild to moderate side effects and no serious side effects reported. The work has an FDA Investigational New Drug clearance, and the method has been licensed to a pharmaceutical company.
These are promising early human results, but ketamine for Parkinson’s dyskinesia is still investigational, not an approved or established treatment. Further Phase 2 trials are ongoing to confirm the benefit and refine dosing. Ketamine is a hopeful research direction for a difficult problem, rather than something patients can access as standard care today.
Frequently Asked Questions
- Can ketamine help with Parkinson’s disease?
- Research suggests it may help with one specific problem: levodopa-induced dyskinesia, the involuntary movements caused by long-term use of the standard Parkinson’s drug. A University of Arizona Phase 2 trial found a single low-dose ketamine infusion eased these movements for several weeks. It is promising but still investigational, not an approved treatment.
- What is levodopa-induced dyskinesia?
- Levodopa-induced dyskinesia is the involuntary, often writhing movements that can develop after years of taking levodopa, the standard Parkinson’s treatment. Levodopa restores dopamine and controls Parkinson’s symptoms, but over time it can cause these movement side effects, which are difficult to treat. This is the specific problem the ketamine research targets.
- How far along is the ketamine Parkinson’s research?
- It has moved from animal studies into human trials. A Phase 2 trial at the University of Arizona found a single low-dose ketamine infusion eased dyskinesia for several weeks and was well tolerated. The work has an FDA Investigational New Drug clearance and has been licensed to a pharmaceutical company, with further trials ongoing. It is not yet an approved treatment.
- Is ketamine an approved treatment for Parkinson’s?
- No. Ketamine for Parkinson’s dyskinesia is investigational and not FDA-approved for that use. The early human results are encouraging, but larger trials are needed to confirm the benefit and safety before it could become standard care. Patients interested in this approach would currently need to access it through a clinical trial.
